Cough, Cold and Allergy Remedies in Indonesia: Market Overview & Outlook 2027-2032

Market Overview

Ask an Indonesian what they do at the first sign of a cold and many will say the same thing: drink a sachet of Tolak Angin or Antangin, rest, and if that does not work, buy Mixagrip or a bottle of OBH Combi from the nearest minimarket. Feeling "masuk angin", literally "wind has entered", is a familiar idea across the country, and treating it early, at home, is a habit passed down through generations.

We estimate retail sales of over-the-counter cough, cold and allergy remedies at about IDR 15.9 trillion in 2025, close to USD 1 billion at IDR 16,400 per dollar. That covers combination cold and flu remedies (both herbal and modern), cough syrups, children's remedies, throat sprays and lozenges, medicated sweets, decongestants and allergy remedies sold without prescription. Value grew about 4% in 2025 and has risen about 31% since 2020, or about 5.6% a year. It works out at about IDR 56,000 per person a year.

Growth has been steady rather than spectacular. Respiratory infections returned as COVID-19 restrictions eased, and value grew about 6–X% a year in 2021 and 2022. The 2022 crisis over contaminated children's syrups dented paediatric sales but did not stop the market, which grew about X.X% in 2023 and about X% in 2024. In 2025 growth of about X% was supported by a wet year and poor air quality in the big cities.

Our estimate sits about X% above published audit data because we add local jamu makers and generic syrups sold in warung and online. Company results are consistent with it: Sido Muncul, maker of Tolak Angin, reported herbal and supplement sales of IDR X.XX trillion in the first nine months of 2025, and Kalbe Farma, owner of Mixagrip, reported 2025 net sales of IDR XX.XX trillion across all its businesses, up X.X%. For a related category, see our report on dietary supplements in Indonesia.

Who Buys Cold and Cough Remedies

The weather sets the calendar. Indonesia has two pancaroba periods a year, the transition between dry and rainy seasons around April–May and October–November, when hot days are followed by sudden downpours. The meteorology agency BMKG regularly warns that these swings weaken immunity, and pharmacies and minimarkets see sales spike. The rainy season itself brings another peak.

Air pollution has become a second driver. The Jakarta Health Office recorded X.XX million cases of acute respiratory infection in the capital between January and October 2025, with a rise from July, and Surabaya also struggles with poor air. Parents of toddlers are especially worried, which supports children's cough and cold remedies, often placed near the checkout in pharmacies and minimarkets for easy purchase when symptoms appear.

Indonesians prefer to treat symptoms early and at home. Most people do not see a doctor for a cold, and campaigns against antibiotic overuse reinforce the habit of using symptom-relief products instead. Consumers increasingly want one product that handles sore throat, cough, congestion and fever together, which explains why combination remedies dominate. For background on household budgets, see our study of purchasing power in Indonesia.

Price points make the habit easy to keep. A sachet of herbal cold remedy costs around IDR X,XXX–4,000, a strip of cold and flu tablets a few thousand rupiah more, and a bottle of cough syrup between IDR XX,XXX and IDR XX,XXX. These are small, urgent purchases that most households make without much price comparison, which is why trusted brands keep their customers for decades and why price increases tend to stick.

Regulation: BPOM, Herbal Medicine and Syrup Safety

Modern cough and cold medicines are registered with BPOM, Indonesia's food and drug authority, and classified as free or limited-free over-the-counter medicines. Herbal remedies follow a separate route as traditional medicines, registered as jamu, standardised herbal medicines or phytopharmaca depending on the level of scientific evidence.

The event that shaped the recent market was the 2022 crisis in which children's syrups contaminated with toxic solvents were linked to acute kidney injury in young children. BPOM tightened testing and pulled products, and many parents switched to trusted brands or herbal alternatives. The episode raised quality costs but strengthened large makers with good manufacturing standards.

The herbal route is a strategic advantage for local companies. Registration as a traditional medicine is lighter than for a new drug, and the government actively promotes herbal medicine. In March 2024 the Ministry of Health and the World Health Organization also launched new guidelines for planning medicine needs, aimed at making safe, essential medicines available nationwide.

Categories: Combination, Cough, Children's and Throat Care

Combination cold and flu remedies make up about two-thirds of value. Cough remedies account for about XX%, children's remedies about XX%, throat preparations about X%, and medicated sweets and decongestants about X% together.

Within combination remedies, herbal and modern products sit side by side. Herbal "masuk angin" liquids such as Tolak Angin and Antangin account for about a quarter of the whole market, a share that has held steady for five years as both sides grew. Modern cold and flu tablets, led by Mixagrip, Ultraflu, Panadol, Decolgen and Neozep, make up the rest. Combination products grew about X.X% a year since 2020, faster than cough syrups at about X.X%. Throat sprays and lozenges grew about X% a year from a small base, helped by pollution. Growth rates and forecasts by category are in the full report.

Innovation is moving in two directions. One is faster-acting formats, such as nasal and throat sprays and lozenges. The other is hybrid products that combine traditional Indonesian ingredients such as ginger, honey and mint with clinically backed actives. Some brands also use QR codes for authenticity checks, a response to concerns about fake medicines.

Behind every sachet sits a supply chain that mixes farm and factory. Herbal makers buy ginger, mint, cloves, honey and other ingredients from Indonesian farmers and process them in their own plants; Sido Muncul is known for controlling its herbal sourcing closely. Modern remedies rely mostly on imported generic actives such as paracetamol, guaifenesin and phenylephrine, formulated locally by companies such as Kalbe, Combiphar and Konimex. In both cases, ingredients are a small part of the shelf price; advertising, distribution and margins make up most of it, which is why the leaders spend so heavily on television and digital campaigns during each cold season.

Channels: Pharmacies, Minimarkets and Warung

Pharmacies and drugstores sell about XX% of value. Chains such as Kimia Farma, K-24 and Century, and thousands of independent pharmacies, are where parents ask about children's syrups and where people go when a cough will not clear.

What makes this category different from most medicines is the role of minimarkets and warung. Herbal sachets and strips of cold tablets are sold like snacks, one at a time, in hundreds of thousands of small shops, so that people can buy them the moment symptoms start. Online sales boomed during the pandemic and have since normalised, but apps such as Halodoc still link consultation with home delivery. For more on the minimarket chains, see our report on convenience retailers in Indonesia. Channel shares over time are in the full report.

Competitive Landscape

Local companies dominate. Sido Muncul (Tolak Angin) leads with about XX% of value, followed by Deltomed (Antangin, OB Herbal) at about XX%, Kalbe Farma (Mixagrip, Woods', Procold) at about XX% and Combiphar (OBH Combi) at about XX%. Konimex, Procter & Gamble (Vicks), Medifarma, Henson Farma and Haleon follow.

The two largest brands are herbal. Tolak Angin and Antangin together hold about a quarter of the market, a striking result in a category that in most countries is dominated by pharmaceutical multinationals. Their makers combine traditional health stories with heavy television and digital advertising and FMCG-style distribution. OBH Combi is the default cough syrup and gained share after the 2022 syrup crisis as parents turned to a trusted name. Among multinationals, Haleon's Panadol has gained the most, while Vicks dominates decongestant rubs.

Shares at the top barely move from year to year, but the leaders face slower growth at home. Sido Muncul is building exports, which already account for about XX% of revenue, and has warned of weaker results in 2026. Kalbe, whose subsidiary Bintang Toedjoe makes the herbal cough syrup Komix, plans price increases. Brand shares, share shifts, category leaders and profiles of the five leading companies are in the full report.

The category is also becoming more medical and more digital at the same time. Awareness of allergic rhinitis and chronic sinusitis is rising among the urban middle class, opening space for allergy-focused products that are still a tiny part of the market. Health apps and teleconsultation services recommend specific products and link users straight to checkout, so being visible in these recommendations matters as much as shelf space. At the other end, prevention-minded consumers are drifting toward immunity and wellness products, blurring the line between cold remedies, herbal tonics and supplements, a space where herbal brands are naturally strong.

What This Means for Brands, Suppliers and Investors

Indonesia's cough and cold market is large, recurring and shaped by weather, pollution and tradition. For brand owners, the lessons are to respect the herbal habit rather than fight it, to own a clear symptom or occasion, and to be available in every minimarket and warung when the rain starts. For ingredient suppliers, standardised ginger, honey and herbal extracts and sugar-free syrup bases are in demand. For manufacturers, quality systems that meet BPOM's tighter syrup rules are now a competitive advantage. For investors, listed herbal and OTC companies with growing exports offer exposure to a resilient category.

This article describes the market as it stands today. The full report adds the price build-up of a herbal sachet and a cough syrup, business models, Porter's Five Forces, eight mega trends, an impact assessment of drivers and restraints, category leaders, sub-category segmentation, five company profiles and bear, base and bull forecasts to 2032.

Key Questions Answered in the Full Report

Cough, Cold and Allergy Remedies in Indonesia: Market Overview & Outlook 2027-2032 Executive Summary

The three slides below summarise the full report. The complete 40-slide version, with the outlook to 2032, value chain, regulation and company profiles, is available on Gumroad.

What the Full Report Includes